Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT03465540
What this trial is testing

Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies

Who this might be right for
Multiple MyelomaAcute Myeloid LeukemiaNon-Hodgkins Lymphoma+4 more
Amgen 24
Testing effectiveness (Phase 2)Study completedNCT03170882
What this trial is testing

Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Millennium Pharmaceuticals, Inc. 122
Testing effectiveness (Phase 2)Looking for participantsNCT06988488
What this trial is testing

Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 62
Testing effectiveness (Phase 2)Active Not RecruitingNCT04094961
What this trial is testing

Ixazomib + Pomalidomide + Dexamethasone In MM

Who this might be right for
Multiple MyelomaMultiple Myeloma in Relapse
Omar Nadeem, MD 52
Early research (Phase 1)Not Yet RecruitingNCT07407010
What this trial is testing

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 10
Testing effectiveness (Phase 2)UnknownNCT03767751
What this trial is testing

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)UnknownNCT01522872
What this trial is testing

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Threshold Pharmaceuticals 98
Testing effectiveness (Phase 2)Study completedNCT02056756
What this trial is testing

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 63
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Ended earlyNCT01670994
What this trial is testing

QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Altor BioScience 6
Large-scale testing (Phase 3)Study completedNCT00799461
What this trial is testing

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+89 more
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium 1,337
Large-scale testing (Phase 3)Study completedNCT01324947
What this trial is testing

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 74
Large-scale testing (Phase 3)Study completedNCT02990338
What this trial is testing

Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 307
Testing effectiveness (Phase 2)Study completedNCT00253578
What this trial is testing

Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
National Cancer Institute (NCI) 40
Early research (Phase 1)Ended earlyNCT03379584
What this trial is testing

A Safety Study of SGN-CD48A in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Seagen Inc. 14
Not applicableStudy completedNCT05887206
What this trial is testing

Corneal Toxicity in Patients Treated by Belantamab Mafodotin

Who this might be right for
Myeloma Multiple
Centre Hospitalier Universitaire de Saint Etienne 43
Testing effectiveness (Phase 2)Study completedNCT01775553
What this trial is testing

Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib

Who this might be right for
Relapse Multiple MyelomaRefractory Multiple Myeloma
Ajai Chari 13
Testing effectiveness (Phase 2)UnknownNCT02248402
What this trial is testing

Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chonnam National University Hospital 15
Very early researchUnknownNCT04626752
What this trial is testing

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd. 50
Early research (Phase 1)Ended earlyNCT04272775
What this trial is testing

MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Takeda 14
Next Page